1. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700–7.
2. U.S. Food & Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry. 2017. Accessed: 30 Jan 2020. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/andas-certain-highly-purified-synthetic-peptide-drug-products-refer-listed-drugs-rdna-origin .
3. European Medicines Agency. Multidisciplinary: biosimilar. 2020. Accessed: 1 Jan 2020. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/multidisciplinary/multidisciplinary-biosimilar .
4. U.S. Food and Drug Administration. Development of Therapeutic Protein Biosimilars: Comparative Analytical Assessment and Other Quality-Related Considerations. Guidance for Industry. Draft Guidance. 2019. Accessed: 30 Jan 2020. Available from: https://www.fda.gov/media/125484/download .
5. Isaacs J, Gonçalves J, Strohal R, Castañeda-Hernández G, Azevedo V, Dörner T, et al. The biosimilar approval process: how different is it? Considerations in Medicine. 2017;1(1):3–6.